MedTrace Logo

Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension

NCT04927299 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2025-03-13

No results posted yet for this study

Summary

Phase IIIb, randomized, double-blind, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination of losartan / chlorthalidone compared with losartan / hydrochlorothiazide in the treatment of patients with essential arterial hypertension.

Conditions

  • Essential Arterial Hypertension

Interventions

DRUG

Losartan/Chlorthalidone in fixed dose

1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg

DRUG

Losartan + hydrochlorothiazide in fixed dose

1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg

Sponsors & Collaborators

  • Laboratorios Silanes S.A. de C.V.

    lead INDUSTRY

Principal Investigators

  • Alberto J Zamora Muciño-Arroyo, M.D · Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V. (BIOMED-AGS)

  • Francisco Padilla Padilla, M.D · Independent

  • Juan A Peraza Zaldivar, M.D · Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V. (BIOMED-GDL)

  • Luis M Román Pintos, PhD · Hospital Hispano S.A. de C.V.

  • Ernesto G Cardona Muñoz, M.D · Independent

  • Cinthia L Patiño Bernal, M.D · CICMEX Centro de Investigación Clínica de México S. de R.L. de C.V.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2023-08-15
Completion
2023-09-11

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04927299 on ClinicalTrials.gov